Bevacizumab is A humanized IgG1 monoclonal antibody that binds with high affinity and specificity to all VEGF-A.
Anal Chem. 2023 Sep 19;95(37):14094-14100.
Amplification-Free Ratiometric Electrochemical Aptasensor for Point-of-Care Detection of Therapeutic Monoclonal Antibodies
Bevacizumab purchased from AbMole
EMBO Mol Med. 2022 May 9;14(5):e14844.
SARS‐CoV‐2 spike spurs intestinal inflammation via VEGF production in enterocytes
Bevacizumab purchased from AbMole
| Cell Experiment | |
|---|---|
| Cell lines | NSCLC cell lines |
| Preparation method | Six NSCLC cell lines were seeded (~2,000–5,000 cells per well, depending on cell type) onto 96-well plates. After 24 h of incubation, cells were treated with erlotinib (0–20 µmol/L), bevacizumab (0–20 ng/mL) or a combination of these agents (erlotinib 1 µmol/L; bevacizumab 10 ng/mL) for 72 h in serum-containing medium. The viability was determined by MTS assay (Promega, Madison, WI) according to the manufacturer’s instructions. |
| Concentrations | 0–20 ng/mL |
| Incubation time | 72 h |
| Animal Experiment | |
|---|---|
| Animal models | Female Wistar rats |
| Formulation | 0.9%sodium chloride solution |
| Dosages | 30 mg/kg |
| Administration | i.p. |
| CAS Number | 216974-75-3 |
| Solubility (25°C) | Water PBS |
| Storage | Store at -20°C or -70°C. Avoid multiple freeze-thaws. |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
[1] Liu W, et al. Eye Sci. Effect of Avastin on the migration and invasion of pterygium fibroblasts.
| Related VEGFR/PDGFR Products |
|---|
| Isolinderalactone
Isolinderalactone suppresses human glioblastoma growth and angiogenic activity through the inhibition of VEGFR2 activation in endothelial cells. Isolinderalactone suppressed the expression of B-cell lymphoma 2 (BCL-2), as well as of survivin and X-linked inhibitor of apoptosis protein (XIAP). |
| Oglufanide
Oglufanide (H-Glu-Trp-OH) is a dipeptide immunomodulator isolated from calf thymus. |
| KLTWQELYQLKYKGI
KLTWQELYQLKYKGI (QK) is a VEGF mimicking peptide, binds to the VEGF receptors and competes with VEGF. |
| Protein LMWP
Protein LMWP is a cell-penetrating peptide with vascular endothelial growth factor (VEGF) inhibitory activity. |
| CBO-P11
CBO-P11 specifically binds to receptor of VEGFR-2 and is used as targeting ligand for tumor angiogenesis. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
